Core A represents the Administrative Core for this P01 application and contains within it, the Biostatistics subcore. Core A will coordinate the overall interactions among the research projects and core facilities and provide frequent forums for the dissemination of information within the P01 group of investigators and within the greater UPMC/UPCI GT and Biological Therapeutics working groups. This core will also manage budgetary matters such as accounting and the tracking of expenditures. Additional clerical responsibilities will include, the preparation of manuscripts and progress reports. The design and implementation of our study models and the interpretation of their derivative data will critically depend on the full participation of members of the Biostatistics Center, who are """"""""housed"""""""" within the Biostatistics sub-core within Core A. Drs. Gooding and Potter will continue to interact with the P01 PIs and with the Program Leader to ensure that the proposed experiments are properly designed and powered, and to assure the most efficient use of animals and patienl materials is made in our preclinical studies. Core A will organize twice monthly P01 research meetings allowing Project and Core personnel to be updated on research progress. Once a month the Project and Core PIs will meet to discuss overall progress, problems, potential solutions and any acute action items. These meetings will be coordinated by Dr. Storkus. In addition, each Project PI will convene his own weekly laboratory meeting. An annual P01 """"""""retreat"""""""" to be held in September or October of each year will be conducted to review the overall progress of the individual projects and the performance of the Core facilites during that year. This meeting will include both internal and external reviewers. These meetings will result in written comments gauging P01 progress and providing recommendations for improved performance to Dr. Storkus, that will be prepared as a yearly Progress Report to be supplied to the NCI'These meetings will also assist Dr. Storkus in the development of new CGT-related projects based on existing knowledge at that time, which will be particularly useful in the design of the competitive P01 renewal application to be generated in YR4.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA100327-05
Application #
7788814
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
5
Fiscal Year
2009
Total Cost
$78,444
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Yang, Chenjie; Ruffner, Melanie A; Kim, Seon-Hee et al. (2012) Plasma-derived MHC class II+ exosomes from tumor-bearing mice suppress tumor antigen-specific immune responses. Eur J Immunol 42:1778-84
Reay, J; Gambotto, A; Robbins, P D (2012) The antitumor effects of adenoviral-mediated, intratumoral delivery of interleukin 23 require endogenous IL-12. Cancer Gene Ther 19:135-43
Zhao, Xi; Bose, Anamika; Komita, Hideo et al. (2012) Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 188:1782-8
Rao, Aparna; Taylor, Jennifer L; Chi-Sabins, Nina et al. (2012) Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res 72:3196-206
Qu, Yanyan; Chen, Lu; Lowe, Devin B et al. (2012) Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Mol Ther 20:644-51
Qu, Y; Taylor, J L; Bose, A et al. (2011) Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther 18:663-73
Lowe, Devin B; Storkus, Walter J (2011) Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy 3:1265-74
Zhao, Xi; Bose, Anamika; Komita, Hideo et al. (2011) Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther 19:805-14
Zhu, Xinmei; Fallert-Junecko, Beth A; Fujita, Mitsugu et al. (2010) Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 59:1401-9
Lipscomb, Michael W; Taylor, Jennifer L; Goldbach, Cristina J et al. (2010) DC expressing transgene Foxp3 are regulatory APC. Eur J Immunol 40:480-93

Showing the most recent 10 out of 31 publications